The Hemp Doctor Launches DROP – Fast Acting THC & THCP Mixer
1. DROP | Delta 9 (15mg per 5ml vial) – Delivers a balanced, uplifting high ideal for relaxation, socializing, or everyday stress relief.
2. DROP | THCP (2.5mg per 5ml vial) – A concentrated option for experienced users, offering deeper, longer-lasting effects in a smaller dose.
DROP comes in a compact, travel-ready vial, making it easy to take your THC or THCP liquid mixer anywhere. Each 5ml dose is completely flavorless, so it won't alter the taste of any drink or food.
The way it was designed, DROP will blend seamlessly into 'practically anything,' from water-based beverages, soft food like yogurt, salads, brownies, and more. And unlike traditional cannabinoid oils, it doesn't separate or leave a residue.
Formulated with cutting-edge nano-emulsion technology, DROP is absorbed faster and more efficiently than traditional edibles because the nano-sized cannabinoids bypass the liver's processing. This allows users to feel the effects within minutes rather than waiting hours for results.
All DROP vials are 0-calorie, gluten-free, sugar-free, and vegan. All batches are made with US-grown Farm Bill-compliant organic hemp and tested by third-party labs to ensure purity and potency.
Why DROP is a Game Changer:
Fast-acting nano-emulsion – Onset in minutes
Flavorless and discreet – No smell, no taste
Pocket-sized and portable – Use anywhere
Precisely measured doses – Complete control over every drop
Hemp-derived & compliant – Legal under the 2018 Farm Bill
DROP—Fast Acting Mixer is available at thehempdoctor.com and thdwholesale.com. The Hemp Doctor's main retail store offers single vials and 10-count multipacks, while 50-count value multipacks are available at The Hemp Doctor Wholesale.
Note: Not for use by persons under 21 years old. Do not mix with alcohol.
About The Hemp Doctor
The Hemp Doctor has been providing quality hemp-derived products since 2018. The North Carolina-based company is known for offering cannabinoid products ranging from THCA flower to pre-rolls, concentrates, gummies, and more.
The company stands out for its dedication to producing quality products at par with customer satisfaction. With over 100,000 satisfied returning customers, thousands of subscribers, 5,000+ Yotpo comments, and a Trustpilot rating of 4.6 out of 5 based on 3,730 genuine reviews, The Hemp Doctor has positioned itself as a leader in the industry.
As a company strictly adhering to lawful and safe human consumption, The Hemp Doctor's array of products undergoes third-party DEA-certified lab testing.
Tara Phoenix
The Hemp Doctor
+1 917-797-8347
[email protected]
Visit us on social media:
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the U.S. by 2030, the company announced on Monday. The investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the U.S., AstraZeneca said. The "cornerstone" of the investment is a proposed new multibillion-dollar manufacturing facility in Virginia that will produce drug substances for the company's weight management portfolio that includes oral GLP-1 medications. AstraZeneca said the facility will be its largest single manufacturing investment in the world. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally," AstraZeneca CEO Pascal Soriot said in a statement. "I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly-skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines." Eli Lilly Investing $27B More In Us Manufacturing The investment also includes: expansion of its R&D facility in Gaithersburg, Maryland; R&D center in Kendall Square, Cambridge, Massachusetts; next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continuous manufacturing expansion in Mount Vernon, Indiana; specialty manufacturing expansion in Coppell, Texas; new sites to supply clinical trials; and growing research and development investment in novel medicines. "We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores," Commerce Secretary Howard Lutnick said in a statement. "This historic investment is bringing tens of thousands of jobs to the U.S. and will ensure medicine sold in our country is produced right here." Read On The Fox Business App AstraZeneca also announced last November $3.5 billion of capital investment in the country, focused on R&D and manufacturing. The company said it included $2 billion of new investment that would create more than 1,000 new, high-skilled jobs in the U.S. Who's Investing In America? 23 Big Companies That Just Promised Billions Under Trump Part of the investment included a $300 million cell therapy manufacturing plant located in Maryland that opened in May. Once in operation, the site will use a relatively new cancer treatment called CAR-T cell therapy to help treat blood cancers like lymphoma and leukemia. The U.S. is AstraZeneca's largest market and represents 42% of the company's total revenue. The pharma giant's goal is to increase that figure to 50% by 2030. AstraZeneca employs 18,000 people and supports 92,000 jobs overall in the U.S. It also currently has 19 R&D, manufacturing and commercial sites in the country. The company said it contributed $5 billion directly to the nation's economy and created about $20 billion worth of overall value for the U.S. economy. Monday's announcement marks the latest investment in America under the Trump administration. Other drugmakers, including Bristol Myers Squibb, Roche, Eli Lilly and Johnson & Johnson, previously announced intentions to invest billions in the U.S. for R&D, manufacturing and factory article source: AstraZeneca to invest $50B in US economy by 2030
Bloomberg
2 hours ago
- Bloomberg
EPA Plans to Ditch Linchpin Climate Policy, Washington Post Says
The US Environmental Protection Agency is considering scrapping a landmark almost two-decade old legal opinion that greenhouse gas emissions are harmful to human health, the Washington Post reported. The so-called ' endangerment finding,' published in 2009, has been the legal basis of a wide range of climate rules under the Clean Air Act. A draft proposal to formally abandon the policy is being considered by the EPA, though is still subject to change, the newspaper reported, citing two sources familiar with the details which it didn't name.
Yahoo
7 hours ago
- Yahoo
21-year-old MIT dropouts raise $32M at $300M valuation led by Insight
Karun Kaushik and Selin Kocalar weren't planning to raise a Series A so soon. Their AI compliance startup, Delve, which announced a $3 million seed round in January, was growing fast and signing customers at a steady clip. Then, inbound interest started rolling in, COO Kocalar told TechCrunch. Delve, which automates regulatory compliance with AI agents, ended up fielding multiple term sheets, eventually closing a $32 million Series A at a $300 million valuation. The round was led by Insight Partners, which took up most of the round, with participation from CISOs at Fortune 500 companies. Insight has been 'amazing to work with, and we felt they were the right long-term partner for us,' said the COO. Delve's new valuation represents a roughly 10x jump from its previous round. Similarly, its customer base has grown from the 100 companies it reported back in January to over 500, many of them fast-growing AI startups like recently minted AI unicorn Lovable, Bland, and Wispr Flow. And while the 2-year-old company, made up of AI researchers from MIT, Stanford, and Berkeley, has seemingly struck gold by using AI to eliminate hundreds of hours of manual processes, its story began much differently. Kaushik and Kocalar met as classmates during their freshman year at MIT. Both had deep interests in AI and health tech. Kaushik had already scaled a COVID diagnostic system to thousands of users during the pandemic. In 2023, they began working on an AI-powered medical scribe to help doctors handle patient documentation. However, handling sensitive healthcare information meant they quickly encountered the costly and time-consuming world of HIPAA compliance. Instead of continuing with the medical scribe, they started building tools to help other companies get HIPAA-compliant faster and more affordably. That pivot got the team into Y Combinator last year and helped them raise their seed round from General Catalyst, FundersClub, Soma Capital, and others. The founders dropped out during their sophomore year in 2023. What started with HIPAA quickly expanded. 'As our customer base grew, they started asking for support with other frameworks: SOC 2, PCI, GDPR, ISO, basically the whole alphabet soup of compliance,' Kocalar narrated. Compliance paperwork can be necessary in everything from launching products to closing enterprise deals. But instead of driving growth, its manual work can become a bottleneck. 'Compliance frameworks are standardized. Businesses aren't,' says CEO Kaushik. 'That mismatch is why traditional software breaks down and teams fall back to duct-taped workflows across email, Slack, and shared drives.' Delve replaces that busywork with AI agents that run in the background (after integrating with customers' tools) like internal team members. These agents collect evidence, write reports, update audit logs, and track configuration changes across fragmented systems, automating compliance workflows in real time. Kocalar says compliance is just the wedge into broader back-office operations. Long-term, the AI startup wants to automate a billion hours of other work — eventually expanding into adjacent areas like cybersecurity, risk, and internal governance. Insight Partners' interest reflects this roadmap. 'Since compliance touches every part of how a business runs, from scaling operations to closing deals to building customer trust, modernizing this function will modernize the entire organization,' said Praveen Akkiraju, managing director at Insight. 'That's what makes Delve's approach so important.' Still, the startup won't be without competition. Several AI companies are emerging with agents to automate business workflows. In addition, larger AI labs like OpenAI are releasing general-purpose agents capable of performing complex tasks. That said, Kocalar says these developments are a validation, not a threat, to Delve's business. She points to the company's domain depth in contrast to more general-purpose agents. 'We're positioning ourselves to improve as AI advances and labs roll out more sophisticated agentic technologies. But what truly sets us apart is the deep, domain-specific knowledge we're building into the platform,' she said. 'Compliance is always shifting as new regulations emerge and existing ones evolve, with companies interpreting them in different ways. That's where Delve stands out.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
